tbuckley/cabot-search huggingface dataset:
Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial
Authors: T. J. Kaley, J. J. Raizer, N. Paleologos, T. Kewalramani, S. Grimm, D. N. Louis, J. G. Cairncross, L. E. Abrey
Journal: Journal of Clinical Oncology (2009)

2055 Background: Treatment of anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytomas (AOA) is controversial. Radiotherapy (RT) remains the standard therapy, but not without toxicity. Exploiting the chemosensitivity of these tumors using myeloablative chemotherapy with APBPCR is a potential strategy to defer RT. We previously reported results using induction PCV chemotherapy; subsequently the induction regimen was changed to temozolomide (TMZ) which is reported here. Methods: Patients were treated with six cycles of TMZ at 200mg/m2 on standard 5/28 day schedule. MRI was performed after three cycles and then after six cycles. Patients with surgical gross total resection who maintained response or patients who responded to temozolomide (CR or PR defined as &gt;50% reduction in tumor) were eligible for myeloablative chemotherapy with thiotepa 250mg/m2/day for three days followed by busulfan 3.2mg/kg/day for three days, followed by APBPCR. 1p19q status was analyzed prospectively; however, patients were enrolled without regard to deletion status. Results: 19 patients (16 AO, 2 AOA, 1 low-grade oligodendroglioma with radiographic features suggestive of high-grade tumor) with a median age of 42 (28–56) and KPS of 90 (70–100) were enrolled. 13 patients had co-deletion of 1p/19q, 2 had intact 1p/19q, 1 pt had biopsy without enough tissue, and pending in 3. Eleven patients were eligible for APBPCR: 10 patients either maintained surgical CR (9) or had a response to TMZ (1) and went on to transplant; one surgical CR pt refused transplant. Six patients were ineligible for transplant because best response of SD (2), PD (2, both 1p19q intact), insurance denial (2). Two patients are still receiving induction TMZ. Median progression-free (PFS) and overall survivals (OS) have not been reached at a median follow-up of 20 months. 2 of the 10 patients who underwent APBPCR recurred, one at 16.1 and one at 34.2 months. No veno-occlusive disease was observed during transplant and no treatment-related deaths occurred. Conclusions: TMZ followed by myeloablative chemotherapy with APBPCR can be safely administered to newly diagnosed AO patients. [Table: see text]
TCT-580 Optical coherence tomography predictors for edge restenosis after everolimus-eluting stent implantation
Authors: Yasushi Ino, Takashi Kubo, Yoshiki Matsuo, Takeyoshi Kameyama, Hiroki Emori, Hironori Kitabata, Akio Kuroi, Tomoyuki Yamaguchi, Hiroshi Aoki, Tsuyoshi Nishiguchi, Takashi Yamano, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2016)
TCT-696 Oxidative Stress Response in Patients with Severe Aortic Stenosis Undergoing Transcatheter And Surgical Aortic Valve Replacement
Authors: Gabriel Maluenda, Juan Guillermo Gormaz, Michael Mahmoudi, Nick Curzen, Cristian Baeza, Michael W. Howard, Edgardo Sepulveda, Marcia Erazo, Nicolas Valls, Abraham Gajardo, Maria Jesus Vergara, Rosario Bravo
Journal: Journal of the American College of Cardiology (2016)
Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Authors: Benedict Fallet, Kerstin Narr, Yusuf I. Ertuna, Melissa Remy, Rami Sommerstein, Karen Cornille, Mario Kreutzfeldt, Nicolas Page, Gert Zimmer, Florian Geier, Tobias Straub, Hanspeter Pircher, Kevin Larimore, Philip D. Greenberg, Doron Merkler, Daniel D. Pinschewer
Journal: Science Immunology (2016)

Interferon-driven inflammation in chronic viral infection blocks generation of sustained B cell responses. See related Research Articles by Moseman et al. and Sammicheli et al. and a Focus by Laidlaw et al.
Glucocorticoids for Acute Viral Bronchiolitis in Infants and Young Children
Authors: Ricardo M. Fernandes, Lisa Hartling
Journal: JAMA (2013)

Are glucocorticoids, alone or combined with bronchodilators, associated with reduced admission rates, length of stay, or improvements in clinical severity scores without increased adverse effects in infants and young children with acute viral bronchiolitis?There is no consistent clinically relevant association of single therapy with systemic or inhaled glucocorticoids and improved outcomes in either outpatient or inpatient settings. Exploratory evidence suggests that combined glucocorticoids and nebulized epinephrine may be associated with lower hospitalization rates in outpatients, but these findings must be interpreted cautiously.
The 3'-5' Exonuclease, TREX1, Interacts with Poly(ADP-ribose) Polymerase-1 (PARP1) in Response to DNA Damage
Authors: Takuya Miyazaki, Yong-Soo Kim, Jeong-Heon Yoon, Hongsheng Wang, Herbert C. Morse
Journal: Blood (2012)
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
Authors: Erin A. Marshall, Kevin W. Ng, Sonia H. Y. Kung, Emma M. Conway, Victor D. Martinez, Elizabeth C. Halvorsen, David A. Rowbotham, Emily A. Vucic, Adam W. Plumb, Daiana D. Becker-Santos, Katey S. S. Enfield, Jennifer Y. Kennett, Kevin L. Bennewith, William W. Lockwood, Stephen Lam, John C. English, Ninan Abraham, Wan L. Lam
Journal: Molecular Cancer (2016)

Lung cancer is a leading cause of cancer-related deaths worldwide. Lung cancer risk factors, including smoking and exposure to environmental carcinogens, have been linked to chronic inflammation. An integral feature of inflammation is the activation, expansion and infiltration of diverse immune cell types, including CD4+ T cells. Within this T cell subset are immunosuppressive regulatory T (Treg) cells and pro-inflammatory T helper 17 (Th17) cells that act in a fine balance to regulate appropriate adaptive immune responses. In the context of lung cancer, evidence suggests that Tregs promote metastasis and metastatic tumor foci development. Additionally, Th17 cells have been shown to be an integral component of the inflammatory milieu in the tumor microenvironment, and potentially involved in promoting distinct lung tumor phenotypes. Studies have shown that the composition of Tregs and Th17 cells are altered in the tumor microenvironment, and that these two CD4+ T cell subsets play active roles in promoting lung cancer progression and metastasis. We review current knowledge on the influence of Treg and Th17 cells on lung cancer tumorigenesis, progression, metastasis and prognosis. Furthermore, we discuss the potential biological and clinical implications of the balance among Treg/Th17 cells in the context of the lung tumor microenvironment and highlight the potential prognostic function and relationship to metastasis in lung cancer.
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
Authors: Karim Chamie, Nicholas M. Donin, Pia Klöpfer, Paul Bevan, Barbara Fall, Olaf Wilhelm, Stephan Störkel, Jonathan Said, Michael Gambla, Robert E. Hawkins, Gustavo Jankilevich, Anil Kapoor, Evgeny Kopyltsov, Michael Staehler, Kimmo Taari, Alberto J. A. Wainstein, Allan J. Pantuck, Arie S. Belldegrun
Journal: JAMA Oncology (2016)

Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Its safety and activity in phase 2 studies prompted investigation into its use as adjuvant monotherapy in participants with high-risk ccRCC.To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.The ARISER trial (Adjuvant Rencarex Immunotherapy Phase 3 Trial to Study Efficacy in Nonmetastatic RCC) was a randomized, double-blind, placebo-controlled phase 3 clinical trial that took place between June 10, 2004, and April 2, 2013, at 142 academic medical centers in 15 countries in North and South America and Europe. Eligible adult patients had undergone partial or radical nephrectomy for histologically confirmed ccRCC and fell into 1 of the following high-risk groups: pT3/pT4Nx/N0M0 or pTanyN+M0 or pT1b/pT2Nx/N0M0 with nuclear grade 3 or greater. Patients were assigned via central computerized double-blind 1:1 randomization to receive either a single loading dose of girentuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24), or placebo, stratified by risk group and region. The data were analyzed from March 31, 2012, to April 2, 2013.Co-primary end points were DFS and OS, based on imaging studies assessed by independent radiological review committee. Secondary end points included safety, assessed as the rate and grade of adverse events.A total of 864 patients (66% male; median [interquartile range] age, 58 [51-65] years) were randomized to girentuximab (n = 433) or placebo (n = 431). Compared with placebo, participants treated with girentuximab had no statistically significant DFS (hazard ratio, 0.97; 95% CI, 0.79-1.18) or OS advantage (hazard ratio, 0.99; 95% CI, 0.74-1.32). Median DFS was 71.4 months (interquartile range, 3 months to not reached) for girentuximab and never reached for placebo group. Median OS was never reached regardless of treatment. Drug-related adverse events occurred in 185 patients (21.6%), reported comparably between arms. Serious adverse events occurred in 72 patients (8.4%), reported comparably between arms. One drug-related serious adverse event occurred in a patient receiving placebo.Girentuximab had no clinical benefit as adjuvant treatment for patients with high-risk ccRCC. The surprisingly long DFS and OS in these patients represent a challenge to adjuvant ccRCC drug development.clinicaltrials.gov Identifier: NCT00087022.
TCT-293 High Syntax score and left main percutaneous coronary intervention in high risk patients. Results at a 10 year follow-up
Authors: Ignacio Sanchez-Perez, Jesus Piqueras-Flores, Alfonso Jurado, María Thiscal López Lluva, Natalia Pinilla-Echeverri, Andrea Moreno-Arciniegas, Manuel Marina-Breysse, Fernando Lozano
Journal: Journal of the American College of Cardiology (2016)
TCT-511 Feasibility of MRI measures for aortic annulus assessment pre TAVR
Authors: Vicente Alcalde-Martinez, Miriam Jimenez, Manuel Lopez Perez, Gerardo Moreno-Terribas, Juan Caballero-Borrego, Joaquin Sanchez Gila, Eduardo Molina Navarro
Journal: Journal of the American College of Cardiology (2016)
Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group
Authors: Caroline Bodet-Milin, Clement Bailly, Michel Meignan, Alina Beriollo-Riedinger, Rene-Olivier Casasnovas, Anne Devillers, Thierry Lamy, Maria Santiago-Ribeiro, Emmanuel Gyan, Céline Gallazzini-Crépin, Remy Gressin, Thomas Carlier, Francoise Kraeber-Bodéré, Olivier Hermine, Steven Le Gouill
Journal: Blood (2015)
Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model
Authors: Hiroshi Yokokawa, Atsunori Higashino, Saori Suzuki, Masaki Moriyama, Noriko Nakamura, Tomohiko Suzuki, Ryosuke Suzuki, Koji Ishii, Kouji Kobiyama, Ken J Ishii, Takaji Wakita, Hirofumi Akari, Takanobu Kato
Journal: Gut (2016)

Objective Although HCV is a major cause of chronic liver disease worldwide, there is currently no prophylactic vaccine for this virus. Thus, the development of an HCV vaccine that can induce both humoural and cellular immunity is urgently needed. To create an effective HCV vaccine, we evaluated neutralising antibody induction and cellular immune responses following the immunisation of a non-human primate model with cell culture-generated HCV (HCVcc). Design To accomplish this, 10 common marmosets were immunised with purified, inactivated HCVcc in combination with two different adjuvants: the classically used aluminum hydroxide (Alum) and the recently established adjuvant: CpG oligodeoxynucleotide (ODN) wrapped by schizophyllan (K3-SPG). Results The coadministration of HCVcc with K3-SPG efficiently induced immune responses against HCV, as demonstrated by the production of antibodies with specific neutralising activity against chimaeric HCVcc with structural proteins from multiple HCV genotypes (1a, 1b, 2a and 3a). The induction of cellular immunity was also demonstrated by the production of interferon-γ mRNA in spleen cells following stimulation with the HCV core protein. These changes were not observed following immunisation with HCVcc/Alum preparation. No vaccination-related abnormalities were detected in any of the immunised animals. Conclusions The current preclinical study demonstrated that a vaccine included both HCVcc and K3-SPG induced humoural and cellular immunity in marmosets. Vaccination with this combination resulted in the production of antibodies exhibiting cross-neutralising activity against multiple HCV genotypes. Based on these findings, the vaccine created in this study represents a promising, potent and safe prophylactic option against HCV.
Sixty seconds on . . . STPs
Authors: Anne Gulland
Journal: BMJ (2016)

Sustainability and transformation plans (STPs) may sound like a boring agenda item, but they have huge implications for the NHS.

The plans, unveiled by NHS England last December, have three overarching aims: to improve health and wellbeing, to improve quality of care, and, crucially, to achieve financial balance. Nigel Edwards, chief executive of the health policy think tank the Nuffield Trust, says that the plans have the “potential to make fundamental changes in the shape and nature of health care services.”1 He warns …
TCT-629 A simple risk model to refine the predictive ability of the STS score for the estimation of early and mid-term mortality in patients undergoing MitraClip implantation
Authors: Carmelo Grasso, Buccheri Sergio, Marco Barbanti, Davide Capodanno, Antonio Popolo Rubbio, Marilena Di Salvo, Salvatore Scandura, Sarah Mangiafico, Sebastiano Imme', Sandra Giaquinta, Giuseppe Ronsivalle, Antonio Condorelli, Piera Capranzano, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2016)
TCT-455 Long-term (≥1 year) Pathological Result of Everolimus-eluting versus Sirolimus-eluting and Bare Metal Stents
Authors: Hiroyoshi Mori, Sho Torii, Kazuyuki Yahagi, Emanuel Harari, Robert Kutys, Maria Romero, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2016)
Judges hear senior surgeon’s appeal against manslaughter conviction
Authors: Clare Dyer
Journal: BMJ (2016)

A senior surgeon jailed for manslaughter after a delay in operating on a patient with a perforated bowel should not have been convicted of causing or significantly contributing to the patient’s death, three judges at the Court of Appeal were told this week.

The patient, James Hughes, was taking an anticoagulant that could have caused him to bleed to death if David Sellu had operated on him earlier, Mark Ellison QC, for Sellu, told the court in the surgeon’s appeal against his conviction.

Sellu, a senior consultant colorectal surgeon, was sentenced to two and a half years in prison in November 2013 for contributing to Hughes’s death in February 2010 at the Clementine Churchill Hospital in Harrow, north London.1 The conviction and sentence, of which Sellu served half in …
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
Authors: Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hossein, Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton, Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou, Frederick Baehner, Maggie Chon U. Cheang, E. Aubrey Thompson
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Genomic data from human epidermal growth factor receptor 2–positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort. Methods: Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna algorithm on the NanoString platform to define intrinsic subtype, risk of recurrence scores, and risk categories for 1392 HER2+ tumors. Subtypes were evaluated for recurrence-free survival (RFS) using Kaplan-Meier and Cox model analysis following adjuvant chemotherapy (n = 484) or chemotherapy plus trastuzumab (n = 908). All statistical tests were two-sided. Results: Patients with HER2+ tumors from N9831 were primarily scored as HER2-enriched (72.1%). These individuals received statistically significant benefit from trastuzumab (hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.52 to 0.89, P = .005), as did the patients (291 of 1392) with luminal-type tumors (HR = 0.52, 95% CI = 0.32 to 0.85, P = .01). Patients with basal-like tumors (97 of 1392) did not have statistically significantly better RFS when treated with trastuzumab and chemotherapy compared with chemotherapy alone (HR = 1.06, 95% CI = 0.53 to 2.13, P = .87). Conclusions: The majority of clinically defined HER2-positive tumors were classified as HER2-enriched or luminal using the Prosigna algorithm. Intrinsic subtype alone cannot replace conventional histopathological evaluation of HER2 status because many tumors that are classified as luminal A or luminal B will benefit from adjuvant trastuzumab if that subtype is accompanied by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that assessment of intrinsic subtype may influence treatment, particularly with respect to evaluating alternative therapeutic approaches for that subset of HER2-positive tumors of the basal-like subtype.
Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
Authors: Stacie M. Jones, Scott H. Sicherer, A. Wesley Burks, Donald Y.M. Leung, Robert W. Lindblad, Peter Dawson, Alice K. Henning, M. Cecilia Berin, David Chiang, Brian P. Vickery, Robbie D. Pesek, Christine B. Cho, Wendy F. Davidson, Marshall Plaut, Hugh A. Sampson, Robert A. Wood
Journal: Journal of Allergy and Clinical Immunology (2016)
TCT-551 Impact of Late Acquired Malapposition after Biolimus-eluting and Sirolimus-eluting Stent Implantation on 5-year Clinical Outcomes Following ST-segment Elevation Myocardial Infarction: Intravascular Ultrasound Analysis from the SORT OUT V Trial.
Authors: Lisbeth Antonsen, Evald Christiansen, Michael Maeng, Jan Ravkilde, Knud Noerregaard Hansen, Lars Romer Krusell, Leif Thuesen, Mikkel Hougaard, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2016)
Risk Factors of HHV6 Reactivation and Relationship Between Syndrome of Inappropriate Antidiuretic Hormone Secretion After Stem Cell Transplantation in Pediatric Patients
Authors: Ryoji Kobayashi, Naohisa Toriumi, Makoto Yoshida, Akihiro Iguchi, Takeo Sarashina, Daisuke Suzuki, Hirozumi Sano, Masao Ogata
Journal: Blood (2011)
Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma
Authors: Severine Navarro, Darren A. Pickering, Ivana B. Ferreira, Linda Jones, Stephanie Ryan, Sally Troy, Andrew Leech, Peter J. Hotez, Bin Zhan, Thewarach Laha, Roger Prentice, Tim Sparwasser, John Croese, Christian R. Engwerda, John W. Upham, Valerie Julia, Paul R. Giacomin, Alex Loukas
Journal: Science Translational Medicine (2016)

A secreted hookworm protein in recombinant form acts on dendritic cells to drive the expansion and mucosal homing of regulatory T cells that protect against airway inflammation in mice, and also dampens human dendritic cell and T cell activation.
Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC)
Authors: K. Arnaoutakis, A. B. Morse, S. Ambika, G. Wong, R. Parameswaran
Journal: Journal of Clinical Oncology (2009)

e17545 PBI is a key core competency in fellowship training. Care delivery measurement is increasingly important in medical practice comprising diverse health care professionals. Our MGOC brings together oncology fellows and oncology nurse practitioners (NPs). Long-term survivorship issues like osteoporosis (OP) are important to quality of life. Surgery, chemotherapy or radiation results in early menopause which increase OP risk. Few studies document evaluation of risk of late side effects of cancer therapy. With a retrospective sequential patient (pts) sample, we used American Board of Internal Medicine Practice Improvement Module (ABIM PIM) to assess documented comprehensiveness of OP risk factor evaluation in 25 MGOC pts. ABIM PIM is WBT that enables care process and outcomes assessment in clinical settings compared with national guidelines. Part 1 includes chart abstraction tools, pts, and practice system surveys; part 2 has quality improvement (QI) tools. Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma. 76% received whole pelvic radiation; 24% received brachytherapy. Mean age was 63 years (range 41–87). 67% pts had normal bone density scan. Smoking status (100%); exercise levels (84%) were well documented. Exam documented height (84%), weight (96%), height loss (76%); presence or absence of kyphosis (96%) in the majority. 64% of pts had bone density scans. Vitamin(vit) D levels were documented in 4%. No pts had complete fall risk evaluation, estimated dietary calcium (Ca)/vitamin D intake or documented adequacy of Ca or vit D intake. Counseling for appropriate Ca/vitamin D intake was poor (4%/8%). Counseling for weight bearing exercise (WBE) was poor (8%). We have targeted areas for improvement for part 2: vit D level evaluation, assessment of and counseling for adequate of Ca/ vit D intake and WBE. An improvement plan has been implemented. Reassessment of documentation adequacy will be performed on a systematic random sample of 25 pts in 6 months. The ABIM PIM in OP enables fellows and NPs to identify weaknesses in documentation practices and pt care leading to formal QI plans to address long term survivorship issue of OP in MGOC. No significant financial relationships to disclose.
Prospective Evaluation of Fetal Haemoglobin Induction in Maternal Erythrocytes: A Preliminary Analysis of a Cohort of 345 Parturients
Authors: Pierre-Olivier Gaudreau, Xiaoduan Weng, Marilyn Brillant, Michael Newmarch, Guillaume Lettre, Michele Mahone, Florence Weber, Marie-Josee Bedard, Andre Masse, John Stagg, Vincent-Philippe Lavallee, Denis Soulieres
Journal: Blood (2015)
ACTIVATION OF TRANSFORMING GROWTH-FACTOR-BETA IS INVERSELY CORRELATED WITH 3 MAJOR RISK-FACTORS FOR CORONARY-ARTERY DISEASE - LIPOPROTEIN(A), LDL-CHOLESTEROL AND PLASMINOGEN-ACTIVATOR INHIBITOR-1
Authors: A Chauhan, Nr Williams, Jc Metcalfe, Aa Grace, Ac Liu, Rm Lawn, Pr Kemp, Pm Schofield, Dj Grainger
Journal: Circulation (1994)
MiR-150 Inhibits MLL-AF9 Associated Leukemia By Suppressing Leukemic Stem Cells
Authors: Patali S Cheruku, Marina Bousquet, Guoqing Zhang, Guangtao Ge, Wei Ying, Cong Meng, Andrew Shie, Stephanie Wang, Piu Wong, Gang Wang, Stephen Safe, Beiyan Zhou
Journal: Blood (2013)